Stockscreener 앱 받기
2.22
1.37%
0.03
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Charles Schwab Investment Management Inc. Boosts Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX stock touches 52-week low at $2.31 amid market challenges - Investing.com India
Analytical Overview: Black Diamond Therapeutics Inc (BDTX)’s Ratios Tell a Financial Story - The Dwinnex
Fmr LLC Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks - Simply Wall St
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Fmr LLC Decreases Stock Position in Mobileye Global Inc. (NASDAQ:MBLY) - Defense World
MFA Financial, Inc. (NYSE:MFA) Shares Sold by Fmr LLC - Defense World
BNP Paribas Financial Markets Purchases 111,027 Shares of Under Armour, Inc. (NYSE:UA) - Defense World
Fmr LLC Has $15.49 Million Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
MetLife Investment Management LLC Raises Stake in Smith-Midland Co. (NASDAQ:SMID) - Defense World
BNP Paribas Financial Markets Raises Stake in RadNet, Inc. (NASDAQ:RDNT) - Defense World
Fmr LLC Increases Position in AppFolio, Inc. (NASDAQ:APPF) - Defense World
Fmr LLC Raises Stock Position in ADT Inc. (NYSE:ADT) - Defense World
Charles Schwab Investment Management Inc. Sells 309,336 Shares of Unisys Co. (NYSE:UIS) - Defense World
Point72 Asset Management L.P. Takes $3.03 Million Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - MarketBeat
Vestal Point Capital LP Purchases 2,928,500 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - MarketBeat
Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR
Genesis Therapeutics presents new PI3Kα mutant inhibitors - BioWorld Online
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Decrease in Short Interest - MarketBeat
T. Rowe Price Investment Management, Inc. Expands Stake in Black Diamond Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Black Diamond Therap - GuruFocus.com
What is HC Wainwright's Estimate for BDTX FY2024 Earnings? - MarketBeat
Wedbush Has Optimistic View of BDTX FY2024 Earnings - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond Therapeutics Reports Promising Q3 2024 Results - TipRanks
Black Diamond: Q3 Earnings Snapshot - San Francisco Chronicle
BDTXBlack Diamond Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Black Diamond's BDTX-1535 Shows 42% Response Rate in Lung Cancer Trial, Reports Q3 Results | BDTX Stock News - StockTitan
Black Diamond Group Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 5.9% in October - MarketBeat
Foundations Investment Advisors LLC Has $445,000 Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) looking to reclaim success with recent performance - SETE News
Investing in Black Diamond Therapeutics Inc (BDTX) Is Getting More Attractive - Knox Daily
Results from Black Diamond Therapeutics Inc (BDTX) show potential - US Post News
Market Update: Black Diamond Therapeutics Inc (BDTX) Sees Negative Movement, Closing at 3.33 - The Dwinnex
Dimensional Fund Advisors LP Has $932,000 Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.87 - Knox Daily
FY2024 EPS Estimates for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Increased by Analyst - MarketBeat
Analysts’ Recent Ratings Changes for Black Diamond Therapeutics (BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) is looking forward to a strong quarter - SETE News
Cuts for Black Diamond as runway's end nears - The Pharma Letter
Q3 2024 Earnings Estimate for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Issued By Wedbush - MarketBeat
Layoffs at local cancer drug developer; Flagship names new managing partner - The Business Journals
Black Diamond Therapeutics (NASDAQ:BDTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data (BDTX) - Seeking Alpha
Black Diamond refocuses on lead cancer drug, extends cash runway - Investing.com India
Black Diamond Therapeutics (NASDAQ:BDTX) Given Outperform Rating at Wedbush - MarketBeat
Piper Sandler maintains Overweight rating on Black Diamond Therapeutics shares - Investing.com Canada
2.88%
2.65%
자본화:
|
볼륨(24시간):